Article: Algene Biotechnologies Corporation Announces Results On Late-Onset Alzheimer Disease

MONTREAL, Oct. 15 /PRNewswire/ - Algene Biotechnologies Corporation (Montreal Stock Exchange: AGN.B) announces that it has completed additional series of experiments pertaining to gene discovery in late-onset Alzheimer disease. Algene reports that it has identified 5 loci of interest (i.e. chromosomal regions that could harbor causal genes) for further gene prospection on Alzheimer disease.

"Although these results could still be considered as preliminary" said Dr. Denis Gauvreau, President and CEO of Algene, "we are very enthusiastic about the data as statistical power for these loci is reasonably high, and in any case higher than that established in control ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!